Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database

Actas dermo-sifiliográficas
J Sanz-Buenomembers of the BIOBADADERM group

Abstract

A 5% risk of reactivation of hepatitis B virus (HBV) infection has been reported in patients with diseases other than psoriasis treated with tumor necrosis factor inhibitors. The aim of this study was to investigate the risk of HBV reactivation in patients with a past history of HBV infection who were receiving biologic therapy for psoriasis. This was a multicenter study of 20 patients with psoriasis who were treated with at least 1 biologic agent. All the patients had serologic evidence of past HBV infection (positive total hepatitis B core antibody and negative hepatitis B surface antibody). We analyzed the clinical, serological, and liver function variables recorded before, during, and at the end of follow-up. The viral load at the end of follow-up was also analyzed for all patients. None of the patients fulfilled the criteria for HBV reactivation at the end of a median follow-up period of 40 months. Combining our data with data from other studies of psoriasis patients with a past history of HBV infection who were treated with a biologic, we calculated a maximum estimated risk of HBV reactivation for a mean follow-up period of 30 months of 2.7 reactivations per 100 patients. Biologic therapy did not cause HBV reactivation in...Continue Reading

Associated Clinical Trials

References

Apr 1, 1983·JAMA : the Journal of the American Medical Association·J A Hanley, A Lippman-Hand
Jan 8, 2004·Journal of Hepatology·Miriam J Alter
Feb 15, 2005·Annals of the Rheumatic Diseases·R G B LangleyC E M Griffiths
Jan 29, 2008·Seminars in Arthritis and Rheumatism·Matthew B Carroll, Michael I Bond
May 27, 2009·Journal of the American Academy of Dermatology·Alberto Conde-TaboadaEduardo López-Bran
Aug 29, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·D PathiranaB Rzany
Feb 27, 2010·The British Journal of Dermatology·L NosottiC Bonifati
Jun 26, 2010·Gut·C LorasUNKNOWN GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group
Jan 18, 2012·Archives of Dermatology·Sylvia HsuUNKNOWN National Psoriasis Foundation Medical Board
Mar 23, 2012·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver
Jun 26, 2012·Journal of the American Academy of Dermatology·Amanda AbramsonRobert Perrillo
Feb 27, 2014·Actas dermo-sifiliográficas·C FerrándizM Toro

❮ Previous
Next ❯

Citations

Jun 18, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·D J NoJ J Wu
Dec 12, 2017·The Journal of Dermatology·Masahiro Kamata, Yayoi Tada
Feb 17, 2018·The British Journal of Dermatology·I García-DovalUNKNOWN European Dermato-Epidemiology Network (EDEN)
Jan 19, 2018·The Journal of Dermatological Treatment·Nawaf AlMutairi, Hesham Alaadin Abouzaid
Jul 31, 2018·Expert Review of Anti-infective Therapy·Mariantonietta PisaturoNicola Coppola
Sep 12, 2018·The Annals of Pharmacotherapy·Rhiannon M BathKellie J Goodlet
Jul 28, 2018·The Journal of Dermatological Treatment·Mina AminJashin J Wu
Jun 22, 2019·American Journal of Clinical Dermatology·Stefano PiasericoFrancesco Paolo Russo
May 3, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·L EissingM Augustin
Aug 7, 2019·Experimental and Therapeutic Medicine·Anca RaducanMaria-Magdalena Constantin
Sep 9, 2016·World Journal of Gastroenterology : WJG·Claudio BonifatiLorenzo Nosotti
Feb 23, 2019·Journal of Cutaneous Medicine and Surgery·Susan M PoelmanAndrei I Metelitsa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.